Bio-Rad Laboratories had faced major struggles in the current market situations with stocks facing multiple declines. The Bio-Rad Labs’ stocks were purchased by several market players including Caxton Associates, Ariel Investments, and Dimensional Fund Advisors increasing their positions. The company also encountered stiff competition and diminishing demand in biopharma. Furthermore, Bio-Rad's Q2 earnings surpassed estimates, however, the guidance was lowered. Amidst all these, the Bio-Rad Laboratories shares received an average rating of 'Hold' from brokerages. On the brighter side, it has been noted that they maintained a healthy balance sheet and have the potential to manage their debt. Recently, the company appointed a new President and COO. Despite periodic losses, Bio-Rad’s stocks were bought by Hsbc Holdings and First Eagle Investment Management. Insider selling was reported with COO selling 3,000 shares. Critically, the company lowered its revenue forecast due to weak biotech demand and reported Q2 2024 financial results. In a surprise move, Bio-Rad announced a $500M share repurchase program, presumably to increase shareholder's equity. For the current year, Bio-Rad has a revenue forecast of $2.13/share, which presents an interesting short-term investment choice.
Bio-Rad Laboratories Stocks News Analytics from Sun, 07 Jun 2015 03:49:27 GMT to Sat, 28 Sep 2024 22:06:00 GMT -
Rating 2
- Innovation 4
- Information 5
- Rumor -3
